Document and Entity Information
Document and Entity Information | 3 Months Ended |
Jul. 31, 2019shares | |
Document And Entity Information | |
Entity Registrant Name | BIOSYNERGY INC |
Entity Central Index Key | 0000715812 |
Document Type | 10-Q |
Document Period End Date | Jul. 31, 2019 |
Amendment Flag | false |
Current Fiscal Year End Date | --04-30 |
Is Entity's Reporting Status Current? | Yes |
Entity Filer Category | Non-accelerated Filer |
Entity Common Stock, Shares Outstanding | 14,935,511 |
Document Fiscal Period Focus | Q1 |
Document Fiscal Year Focus | 2019 |
Entity Emerging Growth Company | false |
Entity Small Business | true |
Entity Interactive Data Current | Yes |
Entity Incorportation State Country Code | IL |
Entity File Number | 000-12459 |
Balance Sheets (Unaudited)
Balance Sheets (Unaudited) - USD ($) | Jul. 31, 2019 | Apr. 30, 2019 |
Current assets | ||
Cash | $ 1,213,647 | $ 1,180,125 |
Accounts receivable, trade (Net of allowance for doubtful accounts of $500 at July 31, 2019 and April 30, 2019) | 229,201 | 246,363 |
Inventories | 158,038 | 162,678 |
Prepaid expenses | 50,614 | 57,658 |
Total current assets | 1,651,500 | 1,646,824 |
Property, Plant and Equipment | ||
Equipment | 201,489 | 201,489 |
Leasehold improvements | 25,809 | 25,809 |
(Property Plant and Equipment Gross) | 227,298 | 227,298 |
Less accumulated depreciation and amortization | (216,401) | (214,982) |
Total property, plant and equipment, net | 10,897 | 12,316 |
Operating Lease Right of Use | 66,825 | 89,100 |
Total Operating Lease Right of Use Asset | 66,825 | 89,100 |
Other assets | ||
Patents less accumulated amortization | 115,291 | 118,702 |
Deposits | 5,937 | 5,937 |
Total other assets | 121,228 | 124,639 |
Total Assets | 1,850,450 | 1,872,879 |
Current Liabilities | ||
Accounts payable | 7,299 | 4,538 |
Accrued compensation and payroll taxes | 19,993 | 39,766 |
Accrued vacation | 29,474 | 21,578 |
Other accrued liabilities | 868 | 209 |
Operating lease liability | 67,650 | 90,200 |
Total current liabilities | 125,284 | 156,291 |
Deferred income taxes | 24,272 | 24,272 |
Shareholders equity | ||
Common stock, no par value: 20,000,000 authorized shares issued: 14,935,511 shares outstanding at July 31, 2019 and April 30, 2019 | 660,988 | 660,988 |
Receivable from Affiliate | (19,699) | (19,699) |
Retained earnings | 1,059,605 | 1,051,027 |
Total Shareholders Equity | 1,700,894 | 1,692,316 |
[LiabilitiesAndStockholdersEquity] | $ 1,850,450 | $ 1,872,879 |
Balance Sheets (Parenthetical)
Balance Sheets (Parenthetical) - USD ($) | Jul. 31, 2019 | Apr. 30, 2019 |
Balance Sheets | ||
Net of allowance for doubtful accounts | $ 500 | $ 500 |
Common stock, no par value | 20,000,000 | 20,000,000 |
Authorized shares issued and outstanding | 14,935,511 | 14,935,511 |
Statements of Operations (Unaud
Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
Jul. 31, 2019 | Jul. 31, 2018 | |
Income Statement [Abstract] | ||
Net Sales | $ 316,782 | $ 317,829 |
Cost of Sales | 107,175 | 103,914 |
Gross Profit | 209,607 | 213,915 |
Operating Expenses | ||
Marketing | 47,802 | 45,709 |
General and administrative | 110,516 | 117,340 |
Research and development | 39,921 | 36,920 |
Total Operating Expenses | 198,239 | 199,969 |
Income from Operations | 11,368 | 13,946 |
Other Income | ||
Interest income | 150 | 92 |
Other income | 480 | 480 |
Total Other Income | 630 | 572 |
Net income (loss) before income taxes | 11,998 | 14,518 |
Provision (benefit) for income taxes | 3,420 | 4,139 |
Net Loss | $ 8,578 | $ 10,379 |
Net income per common share-basic and diluted | $ (0.0006) | $ (0.0007) |
Weighted-Average common stock outstanding-basic and diluted | 14,935,511 | 14,935,511 |
Statements of Cash Flows (Unaud
Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | |
Jul. 31, 2019 | Jul. 31, 2018 | |
Cash flows from operating activities | ||
Net income | $ 8,578 | $ 10,379 |
Adjustments to reconcile net loss to cash provided by (used in) operating activities | ||
Depreciation and amortization | 4,830 | 4,089 |
Noncash Lease Expense | 22,275 | 22,275 |
Changes in assets and liabilities | ||
Accounts receivable | 17,162 | 2,534 |
Inventories | 4,640 | 4,941 |
Prepaid expenses and other | 7,044 | 6,618 |
Accounts payable and accrued expenses | (8,457) | (5,621) |
Building lease liability for right of use asset | (22,550) | (22,000) |
Total Adjustments | 24,944 | 12,836 |
Net cash (used in) provided by operating activities | 33,522 | 23,215 |
Increase in cash and cash equivalents | 33,522 | 23,215 |
Cash and Cash Equivalents Beginning Period | 1,180,125 | 1,140,428 |
Cash and Cash Equivalents Ending Period | 1,213,647 | 1,163,643 |
Supplemental Cash Flow Information | ||
Record Right of Use Asset and Operating Lease Liability | $ 178,200 |
Shareholders Equity (Unaudited)
Shareholders Equity (Unaudited) - 3 months ended Jul. 31, 2019 - USD ($) | Retained Earnings | Total |
Beginning Balance at Apr. 30, 2019 | $ 1,692,316 | |
Common Stock Outstanding at Apr. 30, 2019 | 14,935,511 | |
Net Income | $ 10,379 | $ 8,578 |
Ending Balance at Jul. 31, 2019 | $ 1,700,894 |
Company Organization and Descri
Company Organization and Description | 3 Months Ended |
Jul. 31, 2019 | |
Notes to Financial Statements | |
Company Organization and Description | In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments, consisting of normal recurring adjustments which are necessary for a fair presentation of the financial position and results of operations for the periods presented. The unaudited condensed financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all the information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America. These condensed financial statements should be read in conjunction with the audited financial statements and notes included in the Company’s April 30, 2019 Annual Report on Form 10-K/A. The results of operations for the three months ended July 31, 2019 are not necessarily indicative of the operating results for the full year. Biosynergy, Inc. (the Company) was incorporated under the laws of the State of Illinois on February 9, 1976. It is primarily engaged in the development and marketing of medical, consumer and industrial thermometric and thermographic products that utilize cholesteric liquid crystals. The Company’s primary product, the HemoTemp ® |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 3 Months Ended |
Jul. 31, 2019 | |
Notes to Financial Statements | |
Summary of Significant Accounting Policies | Cash The Company maintains all of its cash in various bank deposit accounts, which at times may exceed federally insured limits. No losses have been experienced on such accounts. Receivables Receivables are carried at original invoice less estimates made for doubtful receivables. Management determines the allowances for doubtful accounts by reviewing and identifying troubled accounts on a periodic basis and by using historical experience applied to an aging of accounts. A receivable is considered to be past due if any portion of the receivable balance is outstanding beyond the stipulated due date. Receivables are written off when deemed uncollectible. Recoveries of receivables previously written off are recorded when received. Inventories Inventories are valued at the lower of cost or market using the FIFO (first-in, first-out) method. Depreciation Equipment and leasehold improvements are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Repairs and maintenance are charged to expense as incurred; renewals and betterments which significantly extend the useful lives of existing equipment are capitalized. Significant leasehold improvements are capitalized and amortized over the term of the lease; equipment is depreciated over three to ten years. Depreciation expense was $1,419 and $1,918 for the three month periods ending July 31, 2019 and 2018, respectively. Prepaid Expenses Certain expenses, primarily insurance and income taxes, have been prepaid and will be used within one year. Revenue Recognition In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)", which supersedes the revenue recognition requirements in Accounting Standards Codification (ASC) 605, Revenue Recognition The Company adopted this standard on May 1, 2018, using the modified retrospective approach. The impact of the adoption of ASU 2014-09 on the Company’s condensed consolidated financial statements is as follows: • The Company’s revenue is primarily generated from the sales of products directly to customers or through distribution channels, based on purchase orders and not supply contracts providing for additional goods or services once the products are transferred to the customer. The Company’s performance obligations underlying such sales, and the timing of revenue recognition related thereto, remain substantially unchanged following the adoption of this ASU. • The adoption of ASU No. 2014-09 requires that the Company recognize its sales return allowance on a gross basis rather than as a net liability. As such, the Company now recognizes a return asset for the right to recover the goods returned by the customer, measured at the former carrying amount of the products, less any expected recovery costs (recorded as an increase to prepaid expenses and other current assets), and a return liability for the amount of expected returns (recorded as an increase to other current liabilities). The Company’s analysis of sales returns over the past several years noted that sales returns are nominal and therefore no sales return allowance is deemed necessary. There was no adjustment necessary for fiscal year ending April 30, 2018 or prior in relation to the change in the revenue recognition policy and no significant effects on the first quarter ending July 31, 2019. Shipping and Handling Shipping and handling fees billed to customer, if any, are netted against the related costs which are included in cost of sales. The net cost is not material. Income Taxes Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes related primarily to differences in the methods of accounting for patents, inventories, certain accrued expenses and bad debt expenses for financial and income tax reporting purposes. The deferred income taxes represent the future tax consequences of those differences, which will be taxable in the future. The Company files tax returns in the U.S. federal jurisdiction and with the state of Illinois. Various tax years remain open to examinations, generally for three years after filing, although there are currently no ongoing tax examinations. Management’s policy is to recognize interest and penalties related to uncertain tax positions in income tax expense. The provision (benefit) for income taxes consists of the following components for the three month periods ended July 31: 2019 2018 Current Federal $ 2,280 $ 2,760 State 1,140 1,379 Provision (Benefit) for Income Taxes $ 3,420 $ 4,139 The differences between the U.S. federal statutory tax rate and the Company’s effective tax rate are as follows: Period ended July 31, 2019 2018 U.S. federal statutory tax rate 21.0 % 21.0 % State income tax expense, net of Federal tax benefit 7.5 7.5 Effective Tax Rate 28.5 % 28.5 % Research and Development and Patents Research and development expenditures are charged to operations as incurred. The costs of obtaining patents, primarily legal fees, are capitalized and, once obtained, are amortized over the life of the respective patent on the straight-line method. Patent amortization expense for the three months ended July 31, 2019 and 2018 were $3,411 and $2,171 respectively. Patents relate to products that have been developed and are being marketed by the Company. Patents pending relate to products under development. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Income Per Common Share Income per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Basic and diluted net income per common share is the same for the 1 st Comprehensive Income Components of comprehensive income include amounts that are included in the comprehensive income but are excluded from net income. During the three month periods ending July 31, 2019 and 2018, there were no differences between the Company’s net income and comprehensive income. Fair Value of Financial Instruments The Company evaluates its financial instruments based on current market interest rates relative to stated interest rates, length to maturity and the existence of readily determinable market prices. Based on the Company’s analysis, the fair value of financial instruments recorded on the balances sheets as of July 31, 2019 and April 30, 2019, approximates their carrying value. Segments Accounting standards have established annual reporting standards for an enterprise’s operating segments and related disclosures about its products, services, geographic areas and major customers. The Company’s operations were a single reportable segment and an international segment. The international segment operations are immaterial. See Note 7. Recent Accounting Pronouncements The FASB issues ASUs to amend the authoritative literature in Accounting Standards Certification (ASC). There have been a number of ASUs to date that amend the original text of ASCs. Those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company or (iv) are not expected to have a significant impact on the Company. |
Inventories
Inventories | 3 Months Ended |
Jul. 31, 2019 | |
Inventory Disclosure [Abstract] | |
Inventories | Components of inventories are as follows: July 31, 2019 April 30, 2019 Raw materials $ 112,383 $ 112,499 Work-in-process 31,271 32,882 Finished goods 14,384 17,297 $ 158,038 $ 162,678 |
Common Stock
Common Stock | 3 Months Ended |
Jul. 31, 2019 | |
Notes to Financial Statements | |
Common Stock | The Company’s common stock is traded in the over-the-counter market. However, there is no established public trading market due to limited and sporadic trades. The Company’s common stock is not listed on a recognized market or stock exchange. |
Related Party Transactions
Related Party Transactions | 3 Months Ended |
Jul. 31, 2019 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | The Company and its affiliates are related through common stock ownership as follows as of July 31, 2019: Stock of Affiliates Biosynergy, Inc. F.K. Suzuki International, Inc. Medlab, Inc. F.K. Suzuki International, Inc 30.0 % — % 100.0 % Fred K. Suzuki, Officer 4.1 30.0 — Jeanne S. Addis, Trustee — 28.1 — Mary K. Friske, Officer .3 .7 — Laurence C. Mead, Officer .4 10.0 — Beverly K. Suzuki 2.7 — — Lauane C. Addis, Officer — — — Malcolm MacCoun, Director — — — As of July 31, 2019, $19,699 was due from F. K. Suzuki International, Inc. (“FKSI”). These balances result from an allocation of common expenses charged to FKSI prior to April 30, 2006 offset by advances received from time to time. No interest income is received or accrued by the Company. The financial condition of FKSI is such that it will unlikely be able to repay the Company during the next year without liquidating a portion of its assets, including a portion of its ownership in the Company. As a result, the receivable balance has been reclassified as a contra equity account since April 30, 2006. A board member provided a variety of legal services to the Company in his capacity as a partner in a law firm. Fees for such legal services were approximately $4,624 and $8,706 for the three months ended July 31, 2019 and 2018 respectively. |
Lease Commitments
Lease Commitments | 3 Months Ended |
Jul. 31, 2019 | |
Leases [Abstract] | |
Lease Commitments | On February 25, 2016, the FASB issued Topic 842, Leases. Under its core principle, a lessee will recognize lease assets and liabilities on the balance sheet for all arrangements with terms longer than 12 months. Lessor accounting remains largely consistent with existing U.S. GAAP. At inception, a lessee must classify all leases as either finance or operating. In February 2018, the Company entered into a two-year lease agreement for its current facilities, which started May 1, 2018 and expires on April 30, 2020. Under the new lease standard, which was early-adopted by the Company as of May 1, 2018, the Company’s lease was accounted for as an operating lease. As a result, the Company measured the lease liability using the two year term and rates per the lease agreement and recognized a lease liability, with a corresponding right-of-use asset. A discount was not calculated due to the lease agreement only having a two year term. The operating lease expense for the three months ending July 31, 2019 was $22,275. Retrospective application of the new standard did not render any adjustments since all of the Company’s operating leases were less than one year. Maturities of lease liabilities as of July 31, 2019 are presented in the following table: Year Ending April 30: 2020 66,825 |
Customer Concentration
Customer Concentration | 3 Months Ended |
Jul. 31, 2019 | |
Accounting Policies [Abstract] | |
Customer Concentration | Shipments to one customer amounted to 28.28% of sales during the first three months of Fiscal 2020 compared to 31.87% during the comparative Fiscal 2019 period. As of July 31, 2019, there were outstanding accounts receivable from this customer of $68,161 compared to $66,518 at July 31, 2018. Shipments to another customer amounted to 36.96% of sales during the first three months of Fiscal 2020 and 36.42% of sales during the first three months of Fiscal 2019. As of July 31, 2019, there were outstanding accounts receivable from this customer of $128,026 compared to $123,166 at July 31, 2018. The Company had export sales of $7,310 during the first three months of Fiscal 2020, and export sales of $10,790 during the first three months of Fiscal 2019. The Company also believes that some of its medical devices were sold to distributors within the United States who resold the devices in foreign markets. However, the Company does not have any information regarding such sales and such sales are not considered to be material. |
Depreciation
Depreciation | 3 Months Ended |
Jul. 31, 2019 | |
Accounting Policies [Abstract] | |
Depreciation (Details) | Equipment and leasehold improvements are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Repairs and maintenance are charged to expense as incurred; renewals and betterments which significantly extend the useful lives of existing equipment are capitalized. Significant leasehold improvements are capitalized and amortized over the term of the lease; equipment is depreciated over three to ten years. Depreciation expense was $1,419 and $1,918 for the three month periods ending July 31, 2019 and 2018, respectively. |
Research and Development and Pa
Research and Development and Patents | 3 Months Ended |
Jul. 31, 2019 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Disclosure - Research and Development and Patents | Research and development expenditures are charged to operations as incurred. The costs of obtaining patents, primarily legal fees, are capitalized and, once obtained, are amortized over the life of the respective patent on the straight-line method. Patent amortization expense for the three months ended July 31, 2019 and 2018 were $3,411 and $2,171 respectively. Patents relate to products that have been developed and are being marketed by the Company. Patents pending relate to products under development. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
Jul. 31, 2019 | |
Notes to Financial Statements | |
Cash | The Company maintains all of its cash in various bank deposit accounts, which at times may exceed federally insured limits. No losses have been experienced on such accounts. |
Receivables | Receivables are carried at original invoice less estimates made for doubtful receivables. Management determines the allowances for doubtful accounts by reviewing and identifying troubled accounts on a periodic basis and by using historical experience applied to an aging of accounts. A receivable is considered to be past due if any portion of the receivable balance is outstanding beyond the stipulated due date. Receivables are written off when deemed uncollectible. Recoveries of receivables previously written off are recorded when received. |
Inventories | Inventories are valued at the lower of cost or market using the FIFO (first-in, first-out) method. |
Depreciation | Equipment and leasehold improvements are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Repairs and maintenance are charged to expense as incurred; renewals and betterments which significantly extend the useful lives of existing equipment are capitalized. Significant leasehold improvements are capitalized and amortized over the term of the lease; equipment is depreciated over three to ten years. Depreciation expense was $1,419 and $1,918 for the three month periods ending July 31, 2019 and 2018, respectively. |
Prepaid Expenses | Certain expenses, primarily insurance and income taxes, have been prepaid and will be used within one year. |
Revenue Recognition | In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)", which supersedes the revenue recognition requirements in Accounting Standards Codification (ASC) 605, Revenue Recognition The Company adopted this standard on May 1, 2018, using the modified retrospective approach. The impact of the adoption of ASU 2014-09 on the Company’s condensed consolidated financial statements is as follows: • The Company’s revenue is primarily generated from the sales of products directly to customers or through distribution channels, based on purchase orders and not supply contracts providing for additional goods or services once the products are transferred to the customer. The Company’s performance obligations underlying such sales, and the timing of revenue recognition related thereto, remain substantially unchanged following the adoption of this ASU. • The adoption of ASU No. 2014-09 requires that the Company recognize its sales return allowance on a gross basis rather than as a net liability. As such, the Company now recognizes a return asset for the right to recover the goods returned by the customer, measured at the former carrying amount of the products, less any expected recovery costs (recorded as an increase to prepaid expenses and other current assets), and a return liability for the amount of expected returns (recorded as an increase to other current liabilities). The Company’s analysis of sales returns over the past several years noted that sales returns are nominal and therefore no sales return allowance is deemed necessary. There was no adjustment necessary for fiscal year ending April 30, 2018 or prior in relation to the change in the revenue recognition policy and no significant effects on the first quarter ending July 31, 2019. |
Shipping and Handling | Shipping and handling fees billed to customer, if any, are netted against the related costs which are included in cost of sales. The net cost is not material. |
Income Taxes | Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes related primarily to differences in the methods of accounting for patents, inventories, certain accrued expenses and bad debt expenses for financial and income tax reporting purposes. The deferred income taxes represent the future tax consequences of those differences, which will be taxable in the future. The Company files tax returns in the U.S. federal jurisdiction and with the state of Illinois. Various tax years remain open to examinations, generally for three years after filing, although there are currently no ongoing tax examinations. Management’s policy is to recognize interest and penalties related to uncertain tax positions in income tax expense. The provision (benefit) for income taxes consists of the following components for the three month periods ended July 31: 2019 2018 Current Federal $ 2,280 $ 2,760 State 1,140 1,379 Provision (Benefit) for Income Taxes $ 3,420 $ 4,139 The differences between the U.S. federal statutory tax rate and the Company’s effective tax rate are as follows: Period ended July 31, 2019 2018 U.S. federal statutory tax rate 21.0 % 21.0 % State income tax expense, net of 7.5 7.5 Effective Tax Rate 28.5 % 28.5 % |
Research and Development and Patents | Research and development expenditures are charged to operations as incurred. The costs of obtaining patents, primarily legal fees, are capitalized and, once obtained, are amortized over the life of the respective patent on the straight-line method. Patent amortization expense for the three months ended July 31, 2019 and 2018 were $3,411 and $2,171 respectively. Patents relate to products that have been developed and are being marketed by the Company. Patents pending relate to products under development. |
Use of Estimates | The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. |
Income Per Comon Share | Income per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Basic and diluted net income per common share is the same for the 1 st |
Comprehensive Income | Components of comprehensive income include amounts that are included in the comprehensive income but are excluded from net income. During the three month periods ending July 31, 2019 and 2018, there were no differences between the Company’s net income and comprehensive income. |
Fair Value of Financial Instruments | The Company evaluates its financial instruments based on current market interest rates relative to stated interest rates, length to maturity and the existence of readily determinable market prices. Based on the Company’s analysis, the fair value of financial instruments recorded on the balances sheets as of July 31, 2019 and April 30, 2019, approximates their carrying value. |
Segments | Accounting standards have established annual reporting standards for an enterprise’s operating segments and related disclosures about its products, services, geographic areas and major customers. The Company’s operations were a single reportable segment and an international segment. The international segment operations are immaterial. See Note 7. |
Recent Accounting Pronouncements | The FASB issues ASUs to amend the authoritative literature in Accounting Standards Certification (ASC). There have been a number of ASUs to date that amend the original text of ASCs. Those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company or (iv) are not expected to have a significant impact on the Company. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 3 Months Ended |
Jul. 31, 2019 | |
Notes to Financial Statements | |
Provision (benefit) for Income Taxes | 2019 2018 Current Federal $ 2,280 $ 2,760 State 1,140 1,379 Provision (Benefit) for Income Taxes $ 3,420 $ 4,139 |
Income Tax Rate | Period ended July 31, 2019 2018 U.S. federal statutory tax rate 21.0 % 21.0 % State income tax expense, net of 7.5 7.5 Effective Tax Rate 28.5 % 28.5 % |
Inventories (Tables)
Inventories (Tables) | 3 Months Ended |
Jul. 31, 2019 | |
Inventory Disclosure [Abstract] | |
Inventories | July 31, 2019 April 30, 2018 Raw materials $ 112,383 $ 112,499 Work-in-process 31,271 32,882 Finished goods 14,384 17,297 $ 158,038 $ 162,678 |
Related Party Transactions (Tab
Related Party Transactions (Tables) | 3 Months Ended |
Jul. 31, 2019 | |
Related Party Transactions [Abstract] | |
Stock of Affiliates | Stock of Affiliates Biosynergy, Inc. F.K. Suzuki International, Inc. Medlab, Inc. F.K. Suzuki International, Inc 30.0 % — % 100.0 % Fred K. Suzuki, Officer 4.1 30.0 — Lauane C. Addis, Officer — — — Jeanne S. Addis, Trustee — 28.1 — Mary K. Friske, Officer .3 .7 — Laurence C. Mead, Officer .4 10.0 — Beverly R. Suzuki 2.7 — — Malcolm MacCoun, Director — — — |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies - Income Tax Rate (Details) | 3 Months Ended | |
Jul. 31, 2019 | Jul. 31, 2018 | |
Notes to Financial Statements | ||
U.S. federal statutory tax rate | 21.00% | 21.00% |
State income tax expense, net of Federal tax benefit | 7.50% | 7.50% |
Adjustment for prior year estimates | 0.00% | 0.00% |
Effect of graduated federal tax rates | ||
Effective Tax Rate | 28.50% | 28.50% |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies - Provision for Income Taxes (Details) - USD ($) | 3 Months Ended | |
Jul. 31, 2019 | Jul. 31, 2018 | |
Current | ||
Federal | $ 2,280 | $ 2,760 |
State | 1,140 | 1,379 |
(Provision) benefit for Income Taxes | $ 3,420 | $ 4,139 |
Depreciation (Details Narrative
Depreciation (Details Narrative) - USD ($) | 3 Months Ended | |
Jul. 31, 2019 | Jul. 31, 2018 | |
Accounting Policies [Abstract] | ||
Depreciation Expense | $ 1,419 | $ 1,918 |
Research and Development and _2
Research and Development and Patents (Details Narrative) - USD ($) | 3 Months Ended | |
Jul. 31, 2019 | Jul. 31, 2018 | |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
Patent amortization expense | $ 3,411 | $ 2,171 |
Inventories - Inventories (Deta
Inventories - Inventories (Details) - USD ($) | Jul. 31, 2019 | Apr. 30, 2019 |
Inventory Disclosure [Abstract] | ||
Raw materials | $ 112,383 | $ 112,499 |
Work-in-process | 31,271 | 32,882 |
Finished goods | 14,384 | 17,297 |
[us-gaap:InventoryGross] | $ 158,038 | $ 162,678 |
Related Party Transactions (Det
Related Party Transactions (Details Narrative) - USD ($) | 3 Months Ended | ||
Jul. 31, 2019 | Jul. 31, 2018 | Apr. 30, 2019 | |
Related Party Transactions [Abstract] | |||
Due from affiliate | $ 19,699 | $ 19,699 | |
Legal Fees | $ 4,624 | $ 8,706 |
Lease Commitments - Future Mini
Lease Commitments - Future Minimum Lease Expense (Details) | 3 Months Ended |
Jul. 31, 2019USD ($) | |
Leases [Abstract] | |
Lease Term | 2 years |
Future Minimum Lease Expense | $ 66,825 |
Expected Date of Maturity | Apr. 30, 2020 |
Customer Concentrations (Detail
Customer Concentrations (Details) - USD ($) | 3 Months Ended | |
Jul. 31, 2019 | Jul. 31, 2018 | |
Exports | $ 7,310 | $ 10,790 |
Customer Two | ||
Accounts Receivable | $ 128,026 | $ 123,166 |
Sales | 36.96% | 36.42% |
Customer One | ||
Accounts Receivable | $ 68,161 | $ 66,518 |
Sales | 28.28% | 31.87% |